Translate page

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

  • Importance of QoL assessment in CML
  • Correlation between QoL and adherence to therapy
  • Update on QoL data from the ENEST trials
  • Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures



Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes


  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford

Interview with Dr Johan Richter: Euro-ski trial

Dr. Johan Richter 2You will also find a podcast interview with Dr Johan Richter on stopping tyrosine kinase inhibitors in a large cohort of European myeloid patients: Results of the euro-ski trial on the EHA Learning Center.

To access the video click here and log-in on the EHA Learning Center platform with your EHA login details or create a free account. 






Perspectives on CML in the emerging economic regions

VEP Garcia Gonzalez Perspectives on CML in the emerging economic regions
Interview with Pat Garcia-Gonzalez CEO of The MAX Foundation and recipient of the 2015 iCMLf ERSAP Prize

  • What has been achieved so far to increase global access to therapy and care to patients?
  • What are the biggest challenges still to be met in the emerging regions?
  • What role do public-private partnerships play to grant access to treatment? 
  • What is the vision for CML management in the emerging regions?

Perspectives from PD Dr. Susanne Saußele
Universitätsklinikum Mannheim, Germany

  • Key criteria for treatment discontinuation
  • The impact comorbidity has on TKI decision making
  • Additional chromosomal aberrations - considerations in clinical practice
  • Highlights of EHA

Perspectives from Prof. Francois-Xavier Mahon
University de Bordeaux, France

  • Perspectives on treatment discontinuation
  • Proposed critieria for stopping TKI therapy
  • Highlights of EHA